Is ZNCXF or JNJ a better dividend investment in 2026?

ZNCXF currently yields 3333.33% with a 5% 5-year dividend growth rate. JNJ yields 2.13% with 5.8% growth. The better choice depends on your goal: ZNCXF offers higher current income.

What is the dividend yield difference between ZNCXF and JNJ?

ZNCXF has a forward dividend yield of 3333.33% ($2.00/share annually). JNJ yields 2.13% ($5.20/share annually). The yield gap is 3331.20 percentage points.

Home › Compare › ZNCXF vs JNJ

ZNCXF vs JNJ: Dividend Comparison 2026

ZNCXF yields 3333.33% · JNJ yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ZNCXF wins by $1244041712890.37M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ZNCXF

● Live price

3333.33%

Share price

$0.06

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$1244041712890.40M

Annual income

$1,174,716,366,071,938,000.00

Full ZNCXF calculator →

JNJ

Johnson & Johnson

● Live price

2.13%

Share price

$244.44

Annual div

$5.20

5Y div CAGR

28%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.3K

Annual income

$4,689.40

Full JNJ calculator →

Portfolio growth — ZNCXF vs JNJ

📍 ZNCXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ZNCXF	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ZNCXF + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ZNCXF pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZNCXF

Annual income on $10K today (after 15% tax)

$283,333.33/yr

After 10yr DRIP, annual income (after tax)

$998,508,911,161,147,300.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$180.82/yr

After 10yr DRIP, annual income (after tax)

$3,985.99/yr

At 15% tax rate, ZNCXF beats the other by $998,508,911,161,143,300.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZNCXF + JNJ for your $10,000?

ZNCXF: 50%JNJ: 50%

100% JNJ50/50100% ZNCXF

Portfolio after 10yr

$622020856445.21M

Annual income

$587,358,183,035,971,300.00/yr

Blended yield

94.43%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ZNCXF

No analyst data

Altman Z

-0.1

Piotroski

2/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

-6.4% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZNCXF buys

JNJ buys

No recent congressional trades found for ZNCXF or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricZNCXFJNJ

Forward yield	3333.33% ✓	2.13%
Annual dividend / share	$2.00	$5.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	28% ✓
Portfolio after 10y	$1244041712890.40M ✓	$30.3K
Annual income after 10y	$1,174,716,366,071,938,000.00 ✓	$4,689.40
Total dividends collected	$1239274250481.68M ✓	$15.4K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: ZNCXF vs JNJ ($10,000, DRIP)

Year	ZNCXF Portfolio	ZNCXF Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$344,033	$333,333.33	$10,592	$272.30	+$333.4K → ZNCXF
2	$11,085,665	$10,717,549.33	$11,289	$357.73	+$11.07M → ZNCXF
3	$334,616,633	$322,754,971.08	$12,123	$472.89	+$334.60M → ZNCXF
4	$9,462,934,690	$9,104,894,892.71	$13,141	$629.86	+$9462.92M → ZNCXF
5	$250,766,259,005	$240,640,918,887.41	$14,408	$846.81	+$250766.24M → ZNCXF
6	$6,228,082,462,189	$5,959,762,565,053.11	$16,021	$1,151.60	+$6228082.45M → ZNCXF
7	$144,998,525,500,125	$138,334,477,265,582.72	$18,122	$1,588.22	+$144998525.48M → ZNCXF
8	$3,165,074,899,913,431	$3,009,926,477,628,297.00	$20,930	$2,228.20	+$3165074899.89M → ZNCXF
9	$64,790,043,755,570,470	$61,403,413,612,663,110.00	$24,792	$3,191.91	+$64790043755.55M → ZNCXF
10	$1,244,041,712,890,398,500	$1,174,716,366,071,938,000.00	$30,274	$4,689.40	+$1244041712890.37M → ZNCXF

ZNCXF vs JNJ: Complete Analysis 2026

ZNCXF — Stock

ZincX Resources Corp. engages in the exploration and evaluation of mineral resource properties in Canada. The company explores for zinc, lead, and silver deposits. Its flagship project is the 100% owned Akie property that consists of 46 mineral claims covering an area of approximately 116 square kilometers located in northeastern British Columbia. The company was formerly known as Canada Zinc Metals Corp. and changed its name to ZincX Resources Corp. in May 2018. ZincX Resources Corp. was incorporated in 1988 and is headquartered in Vancouver, Canada.

Full ZNCXF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

📬

Get this ZNCXF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZNCXF vs SCHD ZNCXF vs JEPI ZNCXF vs O ZNCXF vs KO ZNCXF vs MAIN ZNCXF vs ABBV ZNCXF vs MRK ZNCXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.